When was ADC Biotechnology founded?

ADC Biotechnology was founded in 2010 and raised its 1st funding round within a year of its incorporation.

Where is ADC Biotechnology located?

ADC Biotechnology is headquartered in Saint Asaph, United Kingdom. It is registered at 4 Friarsgate, Whitefriars, Chester, Cheshire, United Kingdom, CH1 1XG.

Who is the current CEO of ADC Biotechnology?

Charlie Johnson of ADC Biotechnology.

How many employees does ADC Biotechnology have?

As of Mar 31, 2022, the latest employee count at ADC Biotechnology is 38.

Is ADC Biotechnology a funded company?

ADC Biotechnology is a funded company, having raised a total of $16.2M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Sep 2010.

When was the latest funding round of ADC Biotechnology?

ADC Biotechnology's latest funding was a $***** Series A round on Dec 02, 2020, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In United Kingdom, the Life Sciences Platforms and Tools sector has seen $177M in funding in 2026 to date.

What is the annual revenue of ADC Biotechnology?

Annual revenue of ADC Biotechnology is between £1M and £10M as on Apr 30, 2019

Where does ADC Biotechnology rank among its competitors?

ADC Biotechnology ranks 143rd amongst 2038 active competitors, of which 449 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was One Biosciences, which secured $3.76M in Sep, 2026.

Who are the top competitors of ADC Biotechnology?

ADC Biotechnology's top competitors include Antheia, Synthego and Axol Bioscience. Among them, One Biosciences secured the most recent funding round in September, 2026.

ADC Biotechnology - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

ADC Bio is developing antibody-drug conjugate (ADC). Its proprietary technology called 'Lock-Release' involves conjugation of proteins that are immobilised on solid supports and delivers key product advantages from minimal aggregate formation to minimal residual free drug and enhanced yields. It also provides technical services including conjugation to a variety of toxin payloads, toxin-linker design and synthesis and supply of ADCs for proof of concept and toxicology testing.

Website: adcbio.com
Social
Registered Address: 4 Friarsgate, Whitefriars, Chester, Cheshire, United Kingdom, CH1 1XG

Key Metrics

Founded Year

2010

Location

Saint Asaph, United Kingdom

Stage

Acqui-Hired

Total Funding

$16.2M in 7 rounds

Latest Funding Round

Series A, Dec 02, 2020, $*****

Investors

Maven Capital Partners & 10 more

Ranked

143^rd among 2038 active competitors

Annual Revenue

£1M - £10M as on Apr 30, 2019

Employee Count

38 as on Mar 31, 2022

Similar Companies

Antheia & 2744 more

View ADC Biotechnology's full profile

ADC Biotechnology is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
ADC Biotechnology Ltd CIN: 7235280 , Germany, Active	Apr 25, 2010	£1M - £10M (As on Apr 30, 2019)	38 (As on Mar 31, 2022)

ADC Biotechnology has raised a total funding of $16.2M over 7 rounds. Its first funding round was on Sep 2010. Its latest funding round was a Series A round on Dec 02, 2020 for $*****. 1 investor participated in its latest round. ADC Biotechnology has 11 institutional investors.

Here is the list of recent funding rounds of ADC Biotechnology:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 02, 2020	7549509	Series A	4800313	8966960	7727395	2016603
Nov 14, 2018	3993295	Series A	4010033	6813237	5983473	5190732
Apr 24, 2018	8250699	Series A	6427375	9124051	Downing & 1 more	4319445

Access funding benchmarks and valuations. Sign up today!

View details of ADC Biotechnology's funding rounds and investors

Here are the details of ADC Biotechnology's key team members:

Charlie Johnson: CEO of ADC Biotechnology. They serve on the board of 1 company.

ADC Biotechnology's Board of Directors

ADC Biotechnology's board has 5 active members. Melanie Elizabeth Anne Goward, Tushar Jain Bahadur, Alan Michael Raymond, Kevin Peter Cook and John William Davies are independent board members.

Here is the list of ADC Biotechnology's board of directors:

Name	Type	Representing	Status	Duration
yeyjy{a	Team	-	Past	8y 8m
Melanie Elizabeth Anne Goward	Independent board member	-	Current	9y 1m
ecjroam	Independent board member	-	Current	7y 9m
pb{lhvd	Independent board member	-	Current	2y 8m
eivstmc	Independent board member	-	Current	2y 6m
sdzqjkk	Independent board member	-	Current	7y 6m
uilzdcs	Independent board member	-	Past	5y 4m
mpq{xxg	Independent board member	-	Past	9y 5m
mnhahhn	Independent board member	-	Past	6y 5m
mwyw{jj	Independent board member	-	Past	9y 9m
rbnkory	Independent board member	-	Past	3y 4m
pq{qtxt	Independent board member	-	Past	4y 8m

View details of ADC Biotechnology's Founder profiles and Board Members

ADC Biotechnology's employee count trend

ADC Biotechnology has 38 employees as of Mar 22. The total employee count is 15.0% more than what it was in Mar 21. Here is ADC Biotechnology's employee count trend over the years:

Employee count trend for ADC Biotechnology

Uncover ADC Biotechnology's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ADC Biotechnology include Antheia, Synthego and Axol Bioscience. Here is the list of Top 10 competitors of ADC Biotechnology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	68/100
2nd	Synthego 2012, Redwood City (United States), Acquired	Manufacturer of custom CRISPR gene editors and molecular biology reagents	$460M	8VC, Perceptive Advisors & 31 others	67/100
3rd	Axol Bioscience 2013, Cambridge (United Kingdom), Series A	Provider of human cells, reagents, and reprogramming services	$13.3M	Calculus Capital, Scottish Enterprise & 13 others	65/100
4th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
5th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 15 others	65/100
6th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
7th	Avalyn Pharma 2011, Seattle (United States), Public	Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis	$389M	Perceptive Advisors, Norwest & 22 others	64/100
8th	enGene 1999, Saint laurent (Canada), Public	Developer of oral non-viral gene therapy platform	$54M	Hercules Capital, Lumira Ventures & 15 others	63/100
9th	Watchmaker Genomics 2018, Boulder (United States), Series A	Developer of gene-editing technology	$48.3M	Decheng Capital, Eclipse	63/100
10th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 7 others	63/100
143rd	ADC Biotechnology 2010, Saint Asaph (United Kingdom), Acqui-Hired	Developer of antibody drug conjugate (ADC)	$16.2M	BioScience Managers, Downing & 9 others	47/100